Background: Although the oral glucose tolerance test (OGTT) is the 'gold standard' for diagnosing prediabetes/diabetes, it is inconvenient for the patient and time consuming. The only alternative simple screening test is fasting plasma glucose (FPG). FPG concentrations of 46.0 mmol/L represent prediabetes/ diabetes. FPG concentrations of r6.0 mmol/L may be considered 'normal', although some such patients will demonstrate abnormal glucose tolerance when subjected to an OGTT. We have evaluated the use of glycated haemoglobin (HbA 1c ) as a screening test for diabetes or impaired glucose tolerance (IGT) in patients who have risk factors for diabetes but FPG r6.0 mmol/L.
Introduction
Pre-diabetes, classi¢ed as impaired fasting glucose (IFG) and impaired glucose tolerance (IGT), is a risk category for diabetes and cardiovascular disease (CVD). There is evidence that pre-diabetes shares many of the metabolic abnormalities seen in type 2 diabetes and that diagnosing IGT at an early stage may have the potential to modify the clinical course of diabetes and its complications. 1 The 75 g oral glucose tolerance test (OGTT) using the World Health Organization (WHO) criteria is considered to be the gold standard in the diagnosis of glucose intolerance and diabetes. 2 However, this test is labour-intensive and inconvenient for the patient. The European and American Diabetes Expert Committees recommended that screening for diabetes be accomplished primarily by measuring FPG. They recommended an OGTT for patients with FPG between 6.1 and 7.0 mmol/L and that subjects with plasma glucose r6.0 mmol/L should have yearly assessments. 3, 4 In our clinical practice, we have observed that a signi¢cant proportion of patients with FPG concentrations r6.0 mmol/L have IGT. We have therefore sought an alternative screening method for selecting patients with FPG r6.0 mmol/L who may bene¢t from having their pre-diabetes state identi¢ed using the OGTT. Although the use of glycated haemoglobin (HbA 1c ) as a screening test for diabetes has been debated, 5 we hypothesized that in patients with FPG r6.0 mmol/L but who have risk factors for diabetes, the measurement of HbA 1c may be useful in selecting patients for an OGTT.
Patients and methods
A total of 580 patients who were referred to the metabolic clinic at Russells Hall Hospital and who had at least two risk factors for diabetes underwent an OGTT r 2005 The Association of Clinical Biochemists and HbA 1c measurement. The risk factors for diabetes included obesity, dyslipidaemia, hypertension, a previous history of IGT and a family history of diabetes. The WHO criteria were used for the diagnosis of diabetes or IGT. 5 Plasma glucose was measured using a glucose oxidase method (Vitros 950 AT, Amersham, England) and HbA 1c using an automated cationic non-porous ion exchange HPLC method (Tosoh Corporation, Kanagawa, Japan) certi¢ed by the National Glycohemoglobin Standardization Program. The interassay coe⁄cients of variation (CVs) for glucose were 1.5% and 1.1% at 5.0 and 16.0 mmol/L, respectively. The interassay CVs for HbA 1c were 2.2% and 1.4% for HbA 1c at 5.8% and 10.2%, respectively.
Statistical analysis was performed using SPSS (version 6.0) software. All results, unless otherwise noted, are expressed as means7SEM. Receiver operator curve (ROC) analysis was used to identify the optimal cut-o¡ value for HbA 1c as a diagnostic indicator for abnormal glucose tolerance in patients with FPG r6.0 mmol/L.
Results
Of the 580 patients, 225 (39%) had an initial FPG r6.0 mmol/L (116 men, 109 women; mean age 52.9712.0 years and 53.3713.5 years, respectively). Using the WHO criteria, 173 (76.9%) patients had normal glucose tolerance, 45 (20%) patients had IGT, and 7 (3.1%) patients had diabetes.
There were no signi¢cant di¡erences in either age or gender between those with diabetes or IGT and those with normal glucose tolerance.
In order to determine the utility of HbA 1c as an additional screening tool, patients (n ¼ 52) who were found to have abnormal glucose tolerance (IGT or diabetes) were matched to patients with normal glucose tolerance and identical FPG (mean 5.470.5 mmol/L in both groups, P ¼ 0.49). Patients with abnormal glucose tolerance had a signi¢cantly higher percentage HbA 1c than subjects with normal glucose tolerance (5.970.5% versus 5.270.4%, Po0.001). Using ROC analysis, an HbA 1c of 5.6% gave an optimal sensitivity of 72% and speci¢city of 77% to predict a 2 h plasma glucose Z7.8 mmol/L (Figure 1 ).
Discussion
Current guidelines recommend screening adults over the age of 45 years for diabetes with a FPG, and that the OGTT is only indicated in those with FPG between 6. 1 and 7.0 mmol/L. However, our results show that almost a quarter of patients at high risk with FPG r6.0 mmol/L had either IGT or diabetes and using FPG alone as a screening test would have missed these patients. On the other hand, screening all patients at high risk with an OGTT would be labour-intensive and expensive. Interestingly, the American Expert Committee on the Diagnosis and Classi¢cation of Diabetes has recently acknowledged that the threshold of FPG of 6.0 mmol/L for IFG is high and recommended that the cut-o¡ point be reduced to 5.6 mmol/L. 6 However, even using this lower FPG cut-o¡ point would have detected less than half of our patients with abnormal OGTT.
HbA 1c analysis is a relatively simple test which gives a more comprehensive measure of total glycaemic exposure than FPG and, hence, it may be a better predictor of abnormal glucose tolerance. Although the use of HbA 1c as a diagnostic test in the general population remains controversial, 6 in populations who are at high risk, it has been shown to correlate well with the diagnosis of diabetes. Our results con¢rm that the use of HbA 1c in patients who have FPG r6.0 mmol/L, but who are at a high risk of developing diabetes, may be a useful and cost-e¡ective approach in selecting patients for OGTT. In our study population, using a cut-o¡ level of 5.6% for HbA 1c would detect almost three-quarters of patients with IGT/diabetes and would only subject onequarter of patients with normal glucose tolerance to an unnecessary OGTT. In addition, our results show that in patients with FPG r6.0 mmol/L and HbA 1c level Z6.0%, the diagnosis of pre-diabetes/diabetes is almost certain, therefore requiring a con¢rmatory OGTT. On the other hand, in patients with FPG r6.0 mmol/L and HbA 1c levels o5.0%, abnormal glucose tolerance can be ruled out with 100% certainty, and an OGTT is not indicated.
Lifestyle modi¢cation has recently been shown to be e¡ective in reducing the conversion rate of IGT to type 2 diabetes mellitus. 1 In order to have an e⁄cient intervention, there is a need for a robust and simple screening strategy, which will enable early detection of patients who could bene¢t from lifestyle modi¢cation. Using the combination of FPG and HbA 1c in high-risk populations may represent a reasonable approach to identifying patients requiring an OGTT, even if the fasting plasma glucose is r6.0 mmol/L.
